$ZYME News
Last published 2d ago
- 2d agoZYMEZymeworks Inc. - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 7.01 Item 9.01
- 2d agoZYMEZymeworks Provides Corporate Update and Reports Third Quarter 2026 Financial ResultsGlobeNewswire2026 financial guidance raised to a total revenue range of $337 million to $351 million (previously between $278 million and $292 million) and an Adjusted EBITDA range of $176 million to $190 million (previously between
- 2d agoZYMEZymeworks Provides Corporate Update and Reports Third Quarter 2026 Financial ResultsGlobeNewswireVANCOUVER, British Columbia, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets, while developing a diverse pipeline of novel, multifunctional biotherapeutics, today reported financial results for the third quarter ended September 30, 2026 and provided a summary of recent business highlights. The Company has e ...
- 2w agoZYMEZymeworks Portfolio Update - ZymeworksEarnings Call TranscriptsThank you for standing by. This is the conference operator. Welcome to ZymeWorks conference call and webcast to discuss ZyMeWorks portfolio updates. As a reminder, all participants are in listen-only mode and the confere
- 2w agoFTHZYMEFaeth Appoints Adam Schayowitz, Ph.D., MBA, Head of Research and Development at Zymeworks, to Board of DirectorsBusiness WireDr. Schayowitz brings nearly 20 years of oncology drug development experience, including development leadership roles at Pfizer Oncology and Tesaro Dr. Schayowitz has led dozens of global development programs and led
- 2w agoZYMEZymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting Antibody-Drug Conjugate ZW191 at ESMO Congress 2026GlobeNewswireZW191 demonstrates compelling anti-tumor activity in heavily pretreated patients with platinum-resistant ovarian cancer across folate receptor alpha (FRα) expression levelsConfirmed objective response rates (cORR) of
- 2w agoZYMEZymeworks Enters into an Exclusive Global License and Collaboration Agreement with Roche for ZW209, a Trispecific T cell Engager Targeting DLL3GlobeNewswireZymeworks to receive a $55 million upfront payment and a $40 million payment upon initiation of the Phase 1b trial, with potential for up to $718 million in additional development, commercial and sales-based
- 3w agoZYMEZymeworks Appoints Suzanne Monahan as Senior Vice President, Commercial and General Manager, Theravance BiopharmaGlobeNewswireVANCOUVER, British Columbia , Oct. 19, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (NASDAQ:ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel,
- 3w agoZYMEZymeworks Announces Participation in Upcoming Investor Conferences and Date of Third Quarter 2026 Financial ResultsGlobeNewswireVANCOUVER, British Columbia, Oct. 15, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (NASDAQ:ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel,
- 1mo agoZYMETheravance Biopharma Closing Conference Call - ZYMEWORKS INCEarnings Call TranscriptsThank you for standing by. This is the conference operator. Welcome to the ZomWorks conference call and webcast to discuss the acquisition of Theravance Biopharma. As a reminder, all participants are in a listen-only mod
- 1mo agoZYMEMorgan Stanley 24th Annual Global Healthcare Conference - Zymeworks IncEarnings Call TranscriptsHello, everyone. My name is Frank Tang, and I'm with the Investment Banking Division at Morgan Stanley. Thank you all for joining us for the Fireside Chat with ZymeWorks. I'm joined here today by the Chairman and CEO, Ke
- 1mo agoZYMEZymeworks Inc - 1773667 - Zymeworks IncEarnings Call TranscriptsHello, everyone. My name is Frank Tang, and I'm with the Investment Banking Division at Morgan Stanley. Thank you all for joining us for the Fireside Chat with ZymeWorks. I'm joined here today by the Chairman and CEO, Ke
- 1mo agoZYMEZymeworks Inc - Morgan Stanley 24th Annual Global Healthcare Conference - Zymeworks IncEarnings Call TranscriptsHello, everyone. My name is Frank Tang, and I'm with the Investment Banking Division at Morgan Stanley. Thank you all for joining us for the Fireside Chat with ZymeWorks. I'm joined here today by the Chairman and CEO, Ke
- 2mo agoZYMEU.S. FDA Approves Ziihera® (zanidatamab-hrii) with and without Tislelizumab plus Chemotherapy in First-Line HER2+ Advanced Gastroesophageal AdenocarcinomaGlobeNewswireZiihera plus tislelizumab and chemotherapy approved for first-line treatment of all HER2+ GEA patients (IHC 3+ and IHC 2+/ISH+) regardless of PD-L1 status, providing a new treatment option in front-line GEASecond FDA
- 3mo agoZYMEZymeworks Announces Participation in Upcoming Investor ConferencesGlobeNewswireVANCOUVER, British Columbia, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (NASDAQ:ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel,
- 3mo agoZYMEZymeworks Provides Corporate Update and Reports Second Quarter 2026 Financial ResultsGlobeNewswireAugust 25, 2026 U.S. PDUFA target action date for zanidatamab has potential to unlock a $250 million U.S. approval milestone and up to $190 million in potential additional global regulatory milestonesAcquisition of
- 3mo agoZYMEZymeworks to Report Second Quarter 2026 Financial Results on August 6, 2026GlobeNewswireVANCOUVER, British Columbia, July 16, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (NASDAQ:ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel,
- 4mo agoZYMEZymeworks' Acquisition of Theravance Biopharma - ZymeworksEarnings Call TranscriptsThank you for standing by. This is the conference operator. Welcome to ZymeWorks conference call and webcast to discuss the acquisition of TheraVance Biopharma. As a reminder, all participants are in a listen-only mode a
- 4mo agoZYMETBPHZymeworks to Acquire Theravance Biopharma, Inc.GlobeNewswireAcquisition adds YUPELRI® (revefenacin), the first and only approved nebulized long-acting muscarinic antagonist (LAMA) for the maintenance treatment of COPD to Zymeworks' portfolioAcquisition of Theravance
- 4mo agoZYMEGandeeva and Zymeworks Use Cryo-EM to Accelerate Antibody Drug DiscoveryPR NewswireVancouver-based biotech companies Gandeeva Therapeutics and Zymeworks have partnered to generate cryo-EM–based structural data to augment antibody...
- 5mo agoZYMEZymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting ADC ZW191 at ESMO Gynaecological Cancers Congress 2026GlobeNewswireZW191 demonstrates compelling anti-tumor activity in platinum-resistant ovarian cancer patients regardless of FRα expression levelConfirmed objective response rate (cORR) of 78.6% in FRα-positive (≥75% at PS2+)
- 6mo agoZYMEZymeworks Announces Share Repurchase Program of up to $125 Million of its Common StockGlobeNewswireVANCOUVER, British Columbia, May 14, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (NASDAQ:ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel,
- 6mo agoZYMEZymeworks Announces Participation in Upcoming Investor ConferencesGlobeNewswireVANCOUVER, British Columbia, May 13, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (NASDAQ:ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel,
- 6mo agoZYMEZymeworks Provides Corporate Update and Reports First Quarter 2026 Financial ResultsGlobeNewswireJazz announced U.S. FDA acceptance with Priority Review of Supplemental Biologics License Application (sBLA) for zanidatamab in first-line HER2-positive unresectable locally advanced or metastatic gastroesophageal
- 6mo agoZYMEZymeworks Presents New Phase 1 Data for ZW191, a Folate Receptor Alpha-Targeting ADC at AACR Annual Meeting 2026GlobeNewswireZW191 demonstrates encouraging anti-tumor activity in heavily pretreated ovarian and endometrial cancers, regardless of FRα expressionConfirmed objective response rate (cORR) of 61% at doses 6.4-9.6 mg/kg in platinum
- 6mo agoZYMEZymeworks Presents New Preclinical Data at AACR 2026 Highlighting Broad Antibody-Drug Conjugate Programs Including Novel RAS-Targeting PlatformGlobeNewswireSix poster presentations showcase Zymeworks' next-generation ADC programs, including multiple first-in-class pan-RAS inhibitor ADCs Data highlight efficacy, tumor-selective delivery, and favorable tolerability across
- 6mo agoZYMEZymeworks to Report First Quarter 2026 Financial Results and Host Conference Call on May 7, 2026GlobeNewswireVANCOUVER, British Columbia, April 16, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (NASDAQ:ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel,
- 7mo agoZYMEZymeworks Announces Additional Leadership Appointments to Advance Next Phase of GrowthGlobeNewswire• Adam Schayowitz, Ph.D., MBA appointed as Head of R&D• Scott Platshon appointed as Chief Business Officer VANCOUVER, British Columbia, April 09, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (NASDAQ:ZYME), a
- 7mo agoZYMEZymeworks Appoints Kristin Stafford as Chief Financial OfficerGlobeNewswireVANCOUVER, British Columbia, April 01, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (NASDAQ:ZYME), a biotechnology company managing a portfolio of licensed healthcare assets, while developing a diverse pipeline of novel,
- 7mo agoZYMEZymeworks Receives U.S. FDA Fast Track Designation for ZW191, an FRα-Targeting Antibody-Drug ConjugateGlobeNewswireU.S. FDA Fast Track designation granted to ZW191, an antibody-drug conjugate targeting folate receptor-α (FRα), for the treatment of patients with advanced or metastatic platinum-resistant ovarian cancer (PROC) Ongoing
- 7mo agoZYMEZymeworks Announces Participation in Upcoming Investor ConferencesGlobeNewswireVANCOUVER, British Columbia, March 24, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (NASDAQ:ZYME), a biotechnology company managing a portfolio of licensed healthcare assets, while developing a diverse pipeline of novel,
- 8mo agoRPRXZYMERoyalty Pharma and Zymeworks Enter Into $250 Million Royalty-Backed Note FinancingGlobeNewswireZymeworks to receive $250 million under a royalty-backed note financing from Royalty Pharma with repayments due from 30% of worldwide tiered royalties on Ziihera until fully repaidZymeworks to retain 70% of royalties on
- 8mo agoRPRXZYMEZymeworks and Royalty Pharma Enter into $250 Million Royalty-Backed Note FinancingGlobeNewswireZymeworks to receive $250 million under a royalty-backed note financing from Royalty Pharma with repayments due from 30% of worldwide tiered royalties on Ziihera until fully repaidZymeworks to retain 70% of royalties on
- 8mo agoZYMEZymeworks Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial ResultsGlobeNewswireSupplemental Biologics License Application for Ziihera® (zanidatamab-hrii) to be completed by our partner Jazz in first-line HER2-positive (HER2+) gastroesophageal adenocarcinoma (GEA) during 1Q 2026 in the U.S.
- 9mo agoZYMEZymeworks To Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on March 2, 2026GlobeNewswireVANCOUVER, British Columbia, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (NASDAQ:ZYME), a biotechnology company managing a portfolio of licensed healthcare assets, while developing a diverse pipeline of novel,
- 9mo agoZYMEZymeworks Announces Participation in Upcoming Investor ConferencesGlobeNewswireVANCOUVER, British Columbia, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (NASDAQ:ZYME), a biotechnology company managing a portfolio of licensed healthcare assets, while developing a diverse pipeline of novel,
- 10mo agoZYMEZymeworks Announces Leadership Appointments and Transitions to Align with Evolution of Corporate StrategyGlobeNewswireInvestment industry veteran Mr. Brian Cherry appointed to Board of DirectorsDr. Sabeen Mekan to transition to Chief Medical Officer effective February 1, 2026 and Mark Hollywood promoted to Executive Vice President and
- 10mo agoZYMEZymeworks Outlines Strategic Priorities and Outlook for 2026GlobeNewswirePositive Phase 3 HERIZON-GEA-01 results for Ziihera® (zanidatamab-hrii) in first-line HER2-positive (HER2+) gastroesophageal adenocarcinoma (GEA) presented at ASCO GI Up to $440.0 million in milestone payments
- 10mo agoZYMEZiihera® (zanidatamab-hrii) Combinations Achieve Unprecedented Results in First-Line HER2+ Locally Advanced or Metastatic GEA including more than Two Years Median Overall Survival BenefitGlobeNewswirePositive results from Phase 3 HERIZON-GEA-01 results support Ziihera as the HER2-targeted agent-of-choice in HER2+ first-line metastatic GEA and Ziihera plus chemotherapy to replace trastuzumab as the new standard of
- 11mo agoZYMEZymeworks Announces Participation in Upcoming ConferencesGlobeNewswire• Late-breaking HERIZON-GEA-01 presentation at ASCO GI highlights the expanding clinical profile of Ziihera® across HER2-driven gastrointestinal cancers by partner Jazz • Zymeworks to present a Trial-in-Progress
- 11mo agoZYMEZymeworks Announces Participation in Upcoming Investor ConferencesGlobeNewswireVANCOUVER, British Columbia, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (NASDAQ:ZYME) a biotechnology company managing a portfolio of licensed healthcare assets, while developing a diverse pipeline of novel,
- 11mo agoANVSAVAINTLARXRX+1Longevity-Focused Health Fueling U.S. Anti-Aging Products Market Projected to Reach $27 Billion By 2033GlobeNewswireMarketNewsUpdates News Commentary NEW YORK, Nov. 18, 2025 (GLOBE NEWSWIRE) -- The advance anti-aging therapies market is expanding quickly fueled by a larger senior population and increased consumer focus on
- 11mo agoZYMEZymeworks Appoints Scott Platshon as Acting Chief Investment OfficerGlobeNewswireVANCOUVER, British Columbia, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (NASDAQ:ZYME), a biotechnology company managing a portfolio of licensed healthcare assets, while developing a diverse pipeline of novel,
- 11mo agoZYMEZymeworks Announces Strategic Initiative to Optimize Value of Licensed Products by Building a Diversified Portfolio of Revenue-Generating AssetsGlobeNewswireStrategy will combine internal innovation, licensing, and strategic acquisitions to drive sustainable value creation for shareholdersStrategic initiative follows positive topline results from pivotal Phase 3
- 11mo agoGLMDKBLBRPTXZYMEKey Catalysts Emerge in Oncology, Synthetic Biology, and M&A Activity as Markets OpenGlobeNewswireDENVER, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Markets open this morning with a distinctly biotech-heavy narrative delivering milestone developments. Zymeworks and Jazz Drop Landmark Phase 3 Data: Ziihera Positioned as New
- 11mo agoZYMEZymeworks Announces Positive HERIZON-GEA-01 Phase 3 Results Supporting Ziihera® (zanidatamab-hrii) as HER2-Targeted Agent-of-Choice and New Standard of Care in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal AdenocarcinomaGlobeNewswireZiihera® plus chemotherapy showed a clinically meaningful and statistically significant improvement in PFS versus trastuzumab and chemotherapy, and a clinically meaningful effect with a strong trend toward
- 1y agoZYMEZymeworks Announces Participation in Upcoming Investor ConferencesGlobeNewswireVANCOUVER, British Columbia, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (NASDAQ:ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the
- 1y agoZYMEZymeworks Presents Initial Clinical Data from the Phase 1 trial of ZW191, an Antibody-Drug Conjugate Targeting Folate Receptor-⍺ at AACR-NCI-EORTC ConferenceGlobeNewswirePreliminary efficacy data, combined with a tolerable safety profile, reinforce the potential of ZW191 in patients with advanced solid tumors, including ovarian, endometrial, and non-small cell lung cancer64% overall
- 1y agoZYMEZymeworks to Report Third Quarter 2025 Financial Results and Host Conference Call on November 6, 2025GlobeNewswireVANCOUVER, British Columbia, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (NASDAQ:ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve
- 1y agoZYMEZymeworks to Present Clinical Data from the Phase 1 trial of ZW191, an Antibody-Drug Conjugate Targeting Folate Receptor-⍺, at AACR-NCI-EORTC International ConferenceGlobeNewswirePreliminary data presented at the AACR-NCI-EORTC conference will provide insights into the potential of ZW191 in patients with advanced solid tumors, including ovarian cancer, endometrial cancer, and non-small cell lung